Literature DB >> 20807515

Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.

Anwar Norazit1, Adrian C B Meedeniya, Maria Nga Nguyen, Alan Mackay-Sim.   

Abstract

Rotenone, a mitochondrial complex 1 inhibitor, causes oxidative damage via production of reactive oxygen species. We examined the pathophysiology of neuronal and glial cells of the nigrostriatal pathway following unilateral infusion of varying doses of rotenone into the substantia nigra or medial forebrain bundle of adult male Sprague-Dawley rats, sacrificed 14 and 60 days after infusion. Immunofluorescence techniques were used to qualitatively and quantitatively assay dopaminergic neurons, their projections, glial cells, synapses, and oxidative stress. Rotenone infusion into the substantia nigra at all concentrations caused extensive damage and tissue necrosis, therefore of limited relevance for producing a Parkinson disease model. Infusion of 0.5μg of rotenone targeting the medial forebrain bundle induced oxidative stress in dopaminergic neurons causing ongoing cell stress as defined by an elevation of stress granule and oxidative stress markers. This treatment resulted in the loss of tyrosine hydroxylase immunoreactive cells in the substantia nigra (p≤0.01) and loss of tyrosine hydroxylase immunoreactive nerve fibres and synaptic specialisations in the striatum (p≤0.01). The infusion of 0.5μg of rotenone also caused an increase in astrocytes and microglial cells in the substantia nigra in comparison to control (p≤0.01). We examined the time-dependent reduction of tyrosine hydroxylase-positive nerve fibres and cell bodies in the striatum and substantia nigra respectively, with a progressive reduction evident 60days after infusion (p≤0.01, p≤0.05). Dopaminergic axons exposed to low-dose rotenone undergo oxidative stress, with a resultant ongoing loss of dopaminergic neurons, providing an animal model relevant to Parkinson disease.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807515     DOI: 10.1016/j.brainres.2010.08.070

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Authors:  Camila G Moreira; Janaína K Barbiero; Deborah Ariza; Patrícia A Dombrowski; Pamela Sabioni; Mariza Bortolanza; Claudio Da Cunha; Maria A B F Vital; Marcelo M S Lima
Journal:  Neurotox Res       Date:  2011-09-28       Impact factor: 3.911

2.  SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.

Authors:  Mathew B Wong; Jacob Goodwin; Anwar Norazit; Adrian C B Meedeniya; Christiane Richter-Landsberg; Wei Ping Gai; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-11-15       Impact factor: 3.911

3.  Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.

Authors:  Camila Mouhape; Gustavo Costa; Margot Ferreira; Juan Andrés Abin-Carriquiry; Federico Dajas; Giselle Prunell
Journal:  Neurotox Res       Date:  2018-07-13       Impact factor: 3.911

Review 4.  Parkinson's Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes.

Authors:  Madalina-Andreea Robea; Ioana-Miruna Balmus; Alin Ciobica; Stefan Strungaru; Gabriel Plavan; Lucian Dragos Gorgan; Alexandra Savuca; Mircea Nicoara
Journal:  Oxid Med Cell Longev       Date:  2020-08-18       Impact factor: 6.543

5.  Embelin and levodopa combination therapy for improved Parkinson's disease treatment.

Authors:  Vagdevi Hangarakatte Ramachandra; Senthilkumar Sivanesan; Anand Koppal; Shanmugam Anandakumar; Matthew D Howell; Ethirajan Sukumar; Rajagopalan Vijayaraghavan
Journal:  Transl Neurosci       Date:  2022-06-29       Impact factor: 1.264

6.  Emerging Roles of N6-Methyladenosine (m6A) Epitranscriptomics in Toxicology.

Authors:  Emir Malovic; Alyssa Ealy; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2021-04-27       Impact factor: 4.109

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.